Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients

J Thromb Haemost. 2013 Feb;11(2):381-4. doi: 10.1111/jth.12095.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / analogs & derivatives*
  • Adenosine / therapeutic use
  • Adenosine Diphosphate
  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Humans
  • Myocardial Infarction / blood
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / therapy*
  • Percutaneous Coronary Intervention* / adverse effects
  • Piperazines / therapeutic use*
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Platelet Function Tests
  • Prasugrel Hydrochloride
  • Predictive Value of Tests
  • Purinergic P2Y Receptor Antagonists / therapeutic use*
  • Receptors, Purinergic P2Y12 / blood
  • Receptors, Purinergic P2Y12 / drug effects
  • Thiophenes / therapeutic use*
  • Ticagrelor
  • Time Factors
  • Treatment Outcome

Substances

  • P2RY12 protein, human
  • Piperazines
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Receptors, Purinergic P2Y12
  • Thiophenes
  • Adenosine Diphosphate
  • Prasugrel Hydrochloride
  • Ticagrelor
  • Adenosine